

#11/B



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO. 018733/0942

Applicant: Hans J. HANSEN *et al.*

Title: USE OF BI-SPECIFIC ANTIBODIES FOR PRE-TARGETING
DIAGNOSIS AND THERAPY

Appl. No.: 09/382,186

Filing Date: 08/23/1999

Examiner: D. Saunders

Art Unit: 1644

RECEIVED
DEC 06 2001
TECH CENTER 1600/2900

AMENDMENT AND REQUEST FOR RECONSIDERATION UNDER 37 CFR §1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Official Action dated June 1, 2001, applicants respond as follows:

IN THE SPECIFICATION

Please insert the following amended version of paragraphs in the specification into the record. The changes are shown explicitly in the attached "Versions with Markings to Show Changes Made In the Specification."

Please amend the paragraph bridging pages 12 and 13 as follows:

B1 Carriers having as few as one amine residue may be used, preferably two to ten amino acid residues, if also coupled to other moieties such as chelating agents. Examples include modified amino acids, such as bis-DTPA-lysine, and bis-DTPA-diamine. These agents can be linked covalently to molecules which are to be targeted. The hapten moiety of the carrier portion should be a low molecular weight conjugate, preferably having a